CanSino Coronavirus Vaccine Shows Promise in Mid-Stage Study
- Shares fluctuate as shot’s effectiveness is still uncertain
- Company’s status reinforced as a front-runner in vaccine race
Photographer: Federico Bernini/Bloomberg
This article is for subscribers only.
CanSino Biologics Inc.’s experimental coronavirus vaccine showed promising results in a mid-stage clinical study, paving the way for the next phase of tests as the Chinese company jostles with Western pharma giants to deliver one of the first pandemic vaccines.
The shot was shown to be safe and induced an immune response, according to a study released in the medical journal The Lancet, reinforcing the company’s status as a front-runner in the vaccine race. Still, CanSino shares fluctuated in Hong Kong trading on Tuesday, rising about 1% by noon after erasing an earlier gain of as much as 7.9%.